Xenon Pharmaceuticals PE Ratio 2012-2021 | XENE

Current and historical p/e ratio for Xenon Pharmaceuticals (XENE) from 2012 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Xenon Pharmaceuticals PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Xenon Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 33.66 0.00
2021-06-30 18.62 $-1.52 0.00
2021-03-31 17.90 $-1.01 0.00
2020-12-31 15.38 $-0.81 0.00
2020-09-30 11.07 $-0.89 0.00
2020-06-30 12.54 $-0.97 0.00
2020-03-31 11.34 $-1.34 0.00
2019-12-31 13.11 $-1.54 0.00
2019-09-30 9.01 $-1.41 0.00
2019-06-30 9.86 $-1.71 0.00
2019-03-31 10.16 $-1.79 0.00
2018-12-31 6.31 $-1.58 0.00
2018-09-30 13.20 $-1.74 0.00
2018-06-30 9.20 $-1.54 0.00
2018-03-31 4.90 $-1.50 0.00
2017-12-31 2.83 $-1.72 0.00
2017-09-30 2.95 $-1.59 0.00
2017-06-30 3.15 $-1.67 0.00
2017-03-31 4.00 $-1.68 0.00
2016-12-31 7.70 $-1.48 0.00
2016-09-30 8.10 $-1.43 0.00
2016-06-30 5.90 $-1.19 0.00
2016-03-31 6.99 $-0.84 0.00
2015-12-31 8.04 $-0.91 0.00
2015-09-30 8.26 $0.93 8.88
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.384B $0.032B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00